FDA to Allow Generic Companies to Alter Drug Labels

Published Online: Monday, August 5, 2013
Follow Pharmacy_Times:
The FDA intends to allow generic drug manufacturers to update product safety labels to include new information on potential risks, according to a July 4 report in USA Today.

The FDA announcement, made July 3, follows a Supreme Court ruling that struck down a lawsuit involving adverse effects from a generic medication. The 5-4 ruling follows several similar lawsuits, where the court ruled that generic manufacturers were not liable for product safety label updates after a generic is already on the market.

“When it comes to decisions on safety and approval of prescription medicine, the FDA is best equipped to make judgments that affect patients,” said GPhA President and CEO Ralph G. Neas in a release. “The experts at the FDA alone have the scientific knowledge, regulatory experience, and complete data to make these decisions.”

The FDA announcement also follows years of petitions from consumer advocacy groups requesting easier processes for label safety updates, USA Today noted.

Currently, generic manufacturers can only change product labels if the FDA approves of the changes or if the regulatory agency orders them to make changes.

According to USA Today, GPhA would prefer the labeling changes remain under the jurisdiction of the FDA.

“Decisions on safety and efficacy of prescription drugs should rest in the hands of the FDA, the only body with the scientific knowledge, regulatory experience, and complete data that is needed to make these decisions,” Neas told USA Today.

Related Articles
“The Generic Pharmaceutical Association (GPhA) is deeply disappointed in today’s 21st Century Cures discussion draft. While we appreciate that it is a draft, in its current form, the bill would upset the important balance between creating competition and encouraging innovation in the pharmaceutical marketplace, putting savings at risk and limiting access to affordable medicines for millions of American patients.
The Generic Pharmaceutical Association announced today that Ralph G. Neas, President and CEO, would be stepping down from his position in the fall of 2015.
Community pharmacists are most concerned about below-cost reimbursement for certain generic drugs as well as exclusionary Medicare drug plans according to a survey conducted by the National Community Pharmacists Association that asked its members to help identify the organization’s 2015 priorities.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$